HD-OPM Archive
Topics › Cancer

Metformin improved oral precancer histology in 60% in a small phase IIa trial

Louis Nervegna · Dec 10, 2025 · ♥ 4 reactions · 0 comments · original Facebook post
CancerInsulin resistance & diabetesAging & longevity
↻ This is a repost. The main version (highest ranked) is Metformin gave 60% histological response in oral premalignant lesions (phase IIa) · Dec 28, 2024.
AI summary & key facts

Louis shares a single-arm phase IIa trial of metformin up to 2000 mg/day for 12 weeks in non-diabetic people with oral premalignant lesions. Histological response was 60% (17% complete) while clinical response was 17%, with inhibition of mTOR signaling. It is a small, uncontrolled trial.

(no text — see the shared post below)

Research cited

In a small human trial involving non-diabetics, metformin reversed pre-cancerous lesions in the mouth by inhibiting mTOR signaling.

Quoted:

“BACKGROUND
The aberrant activation of the PI3K/mTOR signaling circuitry is one of the most frequently dysregulated signaling events in head and neck squamous cell carcinoma (HNSCC). Here, we conducted a single-arm, open-label phase IIa clinical trial in individuals with oral premalignant lesions (OPLs) to explore the potential of metformin to target PI3K/mTOR signaling for HNSCC prevention.

METHODS
Individuals with OPLs, but who were otherwise healthy and without diabetes, underwent pretreatment and posttreatment clinical exam and biopsy. Participants received metformin for 12 weeks (week 1, 500 mg; week 2, 1000 mg; weeks 3–12, 2000 mg daily). Pretreatment and posttreatment biopsies, saliva, and blood were obtained for biomarker analysis, including IHC assessment of mTOR signaling and exome sequencing.

RESULTS
Twenty-three participants were evaluable for response. The clinical response rate (defined as a ≥50% reduction in lesion size) was 17%. Although lower than the proposed threshold for favorable clinical response, the histological response rate (improvement in histological grade) was 60%, including 17% complete responses and 43% partial responses. Logistic regression analysis revealed that when compared with never smokers, current and former smokers had statistically significantly increased histological responses (P = 0.016). Remarkably, a significant correlation existed between decreased mTOR activity (pS6 IHC staining) in the basal epithelial layers of OPLs and the histological (P = 0.04) and clinical (P = 0.01) responses.

CONCLUSION
To our knowledge this is the first phase II trial of metformin in individuals with OPLs, providing evidence that metformin administration results in encouraging histological responses and mTOR pathway modulation, thus supporting its further investigation as a chemopreventive agent.”

#metforminHD #cancerHD #mouthcancerHD #mtorHD

← newer: Lifestyle and drug therapy have additive benefits, so prevenolder: A cheaper high-polyphenol cocoa extract alternative to Cocoa →